Live Analyst Rating Changes 36374 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ryan Zimmerman
BTIG

Ryan Zimmerman

BTIG
Wall Street Analyst
★★★☆☆
#2088
on 13Foresight · ranked by our own returns
43%
Success Rate
-0.9%
Average Return
47 of 110 calls profitable · +21.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 43% of Ryan Zimmerman's ratings turned a profit when each position was held for 1 year — averaging -0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

158 Buy 77 Hold 2 Sell
Ryan's Stock Coverage 39 ratings · 2026-10-01
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CARL
Carlsmed, Inc.
 Sep 28, 2026 BUY Strong Buy
+33.4% avg upside
6 analysts
$23.00
63.46% Upside
 · ·
SNN
Smith & Nephew Snats
 Sep 21, 2026 HOLD Buy
+24.9% avg upside
15 analysts
 — -2.2% ·
GMED
Globus Medical
 Sep 18, 2026 HOLD Strong Buy
+23.8% avg upside
24 analysts
 — +1.1% ·
KIDS
OrthoPediatrics
 Sep 15, 2026 BUY Strong Buy
+41.7% avg upside
10 analysts
$29.00
30.23% Upside
 -2.1% ·
SOLV
Solventum Corporation
 Sep 14, 2026 BUY Buy
+3.6% avg upside
16 analysts
$95.00
7.75% Upside
 -0.6% ·
ISRG
Intuitive Surgical
 Sep 07, 2026 BUY Strong Buy
+17.5% avg upside
36 analysts
$469.00
15.41% Upside
 +14.6% ·
MDT
Medtronic
 Sep 01, 2026 BUY Buy
+16.2% avg upside
38 analysts
$100.00
15.88% Upside
 -5.9% ·
ENOV
Enovis
 Sep 01, 2026 BUY Strong Buy
+260.8% avg upside
39 analysts
$36.00
97.09% Upside
 -10.1% ·
PRCT
PROCEPT BioRobotics
 Aug 31, 2026 HOLD Buy
+79.0% avg upside
17 analysts
 — -18.6% ·
SYK
Stryker
 Aug 27, 2026 BUY Strong Buy
+30.6% avg upside
37 analysts
$358.00
29.95% Upside
 -13.5% ·
LNSR
LENSAR
 Aug 20, 2026 BUY Strong Buy
+105.5% avg upside
4 analysts
$10.00
51.80% Upside
 -18.0% ·
GKOS
Glaukos
 Aug 20, 2026 BUY Strong Buy
+7.0% avg upside
21 analysts
$202.00
23.12% Upside
 -14.2% ·
RCEL
Avita Medical
 Aug 19, 2026 BUY Strong Buy
+3.5% avg upside
11 analysts
$11.00
6.25% Downside
 +13.4% ·
GEHC
GE Healthcare Technologies Inc
 Aug 19, 2026 BUY Strong Buy
+26.0% avg upside
23 analysts
$79.00
20.89% Upside
 -14.3% ·
TCMD
Tactile Systems Technology
 Aug 11, 2026 BUY Strong Buy
+82.5% avg upside
8 analysts
$39.00
74.90% Upside
 -6.7% ·
SI
Shoulder Innovations, Inc.
 Aug 07, 2026 BUY Strong Buy
+24.9% avg upside
5 analysts
$26.00
37.63% Upside
 -8.7% ·
ORGO
Organogenesis Holdings
 Aug 07, 2026 HOLD Strong Buy
+741.5% avg upside
8 analysts
 — -25.5% ·
RXST
RxSight
 Aug 06, 2026 HOLD Hold
+87.8% avg upside
13 analysts
 — -23.4% ·
HUMA
Humacyte
 Jul 28, 2026 BUY Strong Buy
+1197.3% avg upside
11 analysts
$2.00
286.31% Upside
 -11.7% ·
ZBH
Zimmer Biomet Holdings
 Jul 23, 2026 HOLD Hold
+28.6% avg upside
38 analysts
 — -1.5% ·
STAA
Staar Surgical
 Jul 16, 2026 HOLD Hold
+53.3% avg upside
16 analysts
 — -22.9% ·
PEN
Penumbra
 Jul 10, 2026 HOLD Buy
+3.7% avg upside
23 analysts
 — -0.0% ·
MOBI
Mobia Medical, Inc.
 Jun 22, 2026 BUY Strong Buy
+124.4% avg upside
4 analysts
$19.00
100.98% Upside
 -31.9% ·
IART
Integra Lifesciences
 Jun 22, 2026 HOLD Buy
+165.3% avg upside
21 analysts
 — -5.5% ·
MDAI
Spectral AI
 May 26, 2026 BUY Strong Buy
+164.4% avg upside
4 analysts
$4.00
140.96% Upside
 -32.1% ·
VCEL
Vericel
 Apr 05, 2026 HOLD Strong Buy
+15.3% avg upside
16 analysts
 — +16.5% ·
XTNT
Xtant Medical Holdings
 Mar 31, 2026 BUY Strong Buy
+1492.6% avg upside
9 analysts
$1.00
181.70% Upside
 -32.1% ·
CH:ALC
Alcon
 Mar 23, 2026 BUY Buy
+32.5% avg upside
36 analysts
$76.73
43.82% Upside
 -8.8% ·
RBOT
Vicarious Surgical
 Nov 13, 2025 HOLD Buy
+15073.6% avg upside
6 analysts
 — -97.2% ·
TMCI
Treace Medical Concepts
 Nov 07, 2025 HOLD Hold
+33.6% avg upside
8 analysts
 — +0.8% ·
OFIX
Orthofix Medical
 Feb 25, 2025 HOLD Buy
+195.5% avg upside
15 analysts
 — -25.5% ·
IRTC
Irhythm Technologies
 Oct 16, 2023 BUY Strong Buy
+45.1% avg upside
20 analysts
$132.00
16.16% Upside
 -26.8% ·
AXGN
AxoGen
 Aug 18, 2023 HOLD Strong Buy
-15.6% avg upside
21 analysts
 — +104.0% ·
PODD
Insulet
 Apr 17, 2023 BUY Strong Buy
+65.8% avg upside
32 analysts
$350.00
168.30% Upside
 -48.2% ·
GE
GE Aerospace
 Apr 10, 2023 HOLD Strong Buy
-25.0% avg upside
50 analysts
 — +108.4% ·
MDWD
Mediwound
 Oct 14, 2022 HOLD Strong Buy
+59.5% avg upside
13 analysts
 — -3.7% ·
ECOR
Electrocore
 Jul 30, 2021 HOLD Strong Buy
+440.5% avg upside
11 analysts
 — -44.6% ·
ABT
Abbott Laboratories
 Aug 27, 2020 HOLD Strong Buy
+17.3% avg upside
36 analysts
 — +13.6% ·
OCGN
Ocugen
 Dec 24, 2018 HOLD Strong Buy
+799.1% avg upside
17 analysts
 — -95.0% ·
🔒 34 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ryan Zimmerman — Frequently Asked Questions
How accurate are Ryan Zimmerman's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Ryan's ratings were profitable over a one-year hold, with an average return of -0.9% per rating, or +21.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Ryan ranked on 13Foresight?
Ryan Zimmerman is currently ranked #2088 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ryan cover?
Ryan most recently has ratings on CARL, SNN, GMED, KIDS, SOLV, ISRG, MDT, ENOV, PRCT, SYK, LNSR, GKOS and 27 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.